arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

INTEGRA LIFESCIENCES HOLDINGS CORP

IART
$17.25 ▲ +0.16 (+0.97%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTEGRA LIFESCIENCES HOLDINGS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth 1.5%
Op. Margin -30.2%
ROIC -25.5%
FCF / Share $-0.40
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity 0.70
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.64B
↑ +1.5%
Net Income Profit after all expenses
$-516.47M
↓ -7337.7%
Operating Margin Operating profit as % of sales
-30.2%
↓ -1810.3% 8th
FCF / Share Free cash flow per share
$-0.40
↓ -224.9%
Long-Term Debt Long-term obligations
$726.56M
↓ -4.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
17
Financial Health
40
Cash Quality
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters